CIA
DNA icon

Capital Impact Advisors’s Ginkgo Bioworks DNA Stock Holding History

Capital Impact Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,217
Closed -$381K – 65
2024
Q1 		$381K Sell
8,217
-4,694
-36% -$243K 0.5% 79
2023
Q4 		$873K Buy
12,911
+8,359
+184% +$512K 1.15% 36
2023
Q3 		$330K Hold
4,552
– – 0.55% 76
2023
Q2 		$339K Hold
4,552
– – 0.37% 123
2023
Q1 		$242K Buy
4,552
+3,363
+283% +$213K 0.3% 142
2022
Q4 		$80.3K Sell
1,189
-185
-13% -$17K 0.08% 228
2022
Q3 		$118K Buy
+1,374
New +$164K 0.12% 216

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital Impact Advisors's DNA Position: Q2 2024 in Review

Capital Impact Advisors sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 8,217 shares — an estimated $381K sold.

Capital Impact Advisors first reported a position in DNA in Q3 2022 and held it in 7 quarters. The position peaked at $873K in Q4 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Capital Impact Advisors reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 8,217 Ginkgo Bioworks shares in Q2 2024, an estimated $381K.
  • Capital Impact Advisors first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 7 quarters.
  • Capital Impact Advisors's Ginkgo Bioworks position peaked at $873K in Q4 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.